Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) and Blueprint Medicines (NASDAQ:BPMC – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.
Insider and Institutional Ownership
86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 28.4% of Bolt Biotherapeutics shares are owned by company insiders. Comparatively, 3.9% of Blueprint Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Bolt Biotherapeutics and Blueprint Medicines’ gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bolt Biotherapeutics | $7.88 million | 5.37 | -$69.20 million | ($1.83) | -0.61 |
| Blueprint Medicines | $249.38 million | 21.69 | -$506.98 million | ($8.36) | -10.57 |
Profitability
This table compares Bolt Biotherapeutics and Blueprint Medicines’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bolt Biotherapeutics | -878.58% | -51.18% | -37.81% |
| Blueprint Medicines | -203.30% | -191.56% | -45.25% |
Risk and Volatility
Bolt Biotherapeutics has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations for Bolt Biotherapeutics and Blueprint Medicines, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bolt Biotherapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Blueprint Medicines | 3 | 2 | 8 | 1 | 2.50 |
Bolt Biotherapeutics currently has a consensus target price of $7.00, indicating a potential upside of 530.63%. Blueprint Medicines has a consensus target price of $85.43, indicating a potential downside of 3.34%. Given Bolt Biotherapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Bolt Biotherapeutics is more favorable than Blueprint Medicines.
Summary
Bolt Biotherapeutics beats Blueprint Medicines on 10 of the 15 factors compared between the two stocks.
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
About Blueprint Medicines
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
